NDC 24201-101 Valrubicin Intravesical Solution

Valrubicin Intravesical Solution

NDC Product Code 24201-101

NDC Code: 24201-101

Proprietary Name: Valrubicin Intravesical Solution What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Valrubicin Intravesical Solution What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

NDC Code Structure

  • 24201 - Leucadia Pharmaceuticals
    • 24201-101 - Valrubicin Intravesical Solution

NDC 24201-101-04

Package Description: 4 VIAL in 1 CARTON > 5 mL in 1 VIAL

NDC Product Information

Valrubicin Intravesical Solution with NDC 24201-101 is a a human prescription drug product labeled by Leucadia Pharmaceuticals. The generic name of Valrubicin Intravesical Solution is valrubicin intravesical solution. The product's dosage form is solution, concentrate and is administered via intravesical form.

Labeler Name: Leucadia Pharmaceuticals

Dosage Form: Solution, Concentrate - A liquid preparation (i.e., a substance that flows readily in its natural state) that contains a drug dissolved in a suitable solvent or mixture of mutually miscible solvents; the drug has been strengthened by the evaporation of its nonactive parts.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Valrubicin Intravesical Solution Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • VALRUBICIN 40 mg/mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • ALCOHOL (UNII: 3K9958V90M)
  • POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)
  • NITROGEN (UNII: N762921K75)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravesical - Administration within the bladder.

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Leucadia Pharmaceuticals
Labeler Code: 24201
FDA Application Number: ANDA206430 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 04-23-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Information for Patients

Valrubicin Intravesical

Valrubicin Intravesical is pronounced as (val roo' bi sin)

Why is valrubicin intravesical medication prescribed?
Valrubicin solution is used to treat a type of bladder cancer (carcinoma in situ; CIS) that was not effectively treated with another medication (Bacillus Calmette-Guerin;...
[Read More]

* Please review the disclaimer below.

Valrubicin Intravesical Solution Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1  Indications And Usage

Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma


in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

For Intravesical Use Only.  Do NOT administer by intravenous or intramuscular routes.Valrubicin intravesical solution is recommended at a dose of 800 mg administered intravesically once a week for six weeks. Delay administration at least two weeks after transurethral resection and/or fulguration [


see Warnings and Precautions (


5.2,


5.3)].

2.2  Preparation, Handling, And Administration

Handle and dispose of valrubicin intravesical solution in a manner consistent with other cytotoxic drugs.


1 The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.


Valrubicin intravesical solution contains polyoxyl castor oil, which has been known to cause leaching of di(2-ethylhexyl) phthalate (DEHP) a hepatotoxic plasticizer, from polyvinyl chloride (PVC) bags and intravenous tubing. Valrubicin intravesical solution should be prepared and stored in glass, polypropylene, or polyolefin containers and tubing. It is recommended that non-DEHP containing administration sets, such as those that are polyethylene-lined, be used.Valrubicin intravesical solution is a sterile, clear red solution. Visually inspect for particulate matter and discoloration prior to administration. At temperatures below 4°C (39°F), polyoxyl castor oil may begin to form a waxy precipitate. If this happens, the vial should be warmed in the hand until the solution is clear. If particulate matter is still seen, do not administer valrubicin intravesical solution.For each instillation, slowly allow four 5 mL vials (200 mg valrubicin/5 mL vial) to warm to room temperature, but do not heat. Withdraw 20 mL of valrubicin intravesical solution from the four vials and dilute with 55 mL of 0.9% Sodium Chloride Injection, USP to provide 75 mL of a diluted valrubicin intravesical solution. Valrubicin intravesical solution diluted in 0.9% Sodium Chloride Injection, USP for administration is stable for 12 hours at temperatures up to 25°C (77°F). Since compatibility data are not available, do not mix valrubicin intravesical solution with other drugs.Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL valrubicin intravesical solution slowly via gravity flow over a period of several minutes.  Withdraw the catheter and retain valrubicin intravesical solution in the bladder for two hours before voiding.  At the end of two hours, all patients should void.  Some patients may be unable to retain the drug for the full two hours. Instruct patients to maintain adequate hydration following valrubicin intravesical solution treatment


[see Patient Counseling Information (


17)]


.

3  Dosage Forms And Strengths

200 mg/5 mL sterile, clear red, solution in single-use vials for intravesical instillation upon dilution.

4  Contraindications

  • Valrubicin intravesical solution is contraindicated in patients with:Perforated bladder [
  • See Warnings and Precautions(
  • 5.2)]
  • Known hypersensitivity to anthracyclines or polyoxyl castor oilActive urinary tract infection Small bladder capacity and unable to tolerate a 75 mL instillation

5.1  Risk Of Metastatic Bladder Cancer With Delayed Cystectomy

Inform patients that valrubicin intravesical solution has been shown to induce complete response in only about 1 in 5 patients with BCG-refractory CIS, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal. The exact risk of developing metastatic bladder cancer from such a delay may be difficult to assess


[see Clinical Studies (


14)]


but increases the longer cystectomy is delayed in the presence of persisting CIS. If there is not a complete response of CIS to treatment after 3 months or if CIS recurs, reconsider cystectomy.

5.2  Risks In Patients With Perforated Bladder

Evaluate the bladder before the intravesical instillation of drug and do not administer valrubicin intravesical solution to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised


[see Contraindications (


4)]


. In case of bladder perforation, delay the administration of valrubicin intravesical solution until bladder integrity has been restored.  One patient with a perforated bladder who received 800 mg of valrubicin intravesical solution intravesically developed severe leukopenia and neutropenia approximately two weeks after drug administration


[see Clinical Pharmacology (


12.3)]


.

5.3  Risk In Patients Undergoing Transurethral Resection Of The Bladder (Turb)

To avoid systemic exposure to valrubicin intravesical solution for the patients undergoing TURB, evaluate the status of the bladder before the intravesical instillation of drug. Delay administration at least two weeks after transurethral resection and/or fulguration.

5.4  Risk In Patients With Irritable Bladder Symptoms

Use valrubicin intravesical solution with caution in patients with severe irritable bladder symptoms. Bladder spasm and spontaneous discharge of the intravesical instillate may occur; clamping of the urinary catheter is not advised.

5.5  Embryo-Fetal Toxicity

Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant woman


[see Clinical Pharmacology (


12.1 and


12.3)]


.  In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions.  Advise females who might become pregnant of the potential risk to a fetus.


Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months following the final dose


[see Use in Specific Populations (


8.1 and


8.3)]


.

6.1  Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The safety of valrubicin intravesical solution was assessed in 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses.  One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks.Approximately 84% of patients who received intravesical valrubicin intravesical solution in clinical studies experienced local adverse reactions. The local adverse reactions associated with valrubicin intravesical solution usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder. Seven out of 143 patients (5%) who were scheduled to receive six doses of valrubicin intravesical solution failed to receive all of the planned doses because of the occurrence of local bladder symptoms.TABLE 1 displays the frequency of the local adverse reactions at baseline and during treatment among 179 patients who received 800 mg doses of valrubicin intravesical solution in a multiple-cycle treatment regimen.                                                                               TABLE 1 Local Adverse Reactions Before and During Treatment with Valrubicin Intravesical Solution (N=179) Adverse ReactionBefore TreatmentDuring 6-weekCourse of TreatmentANY LOCALBLADDER SYMPTOM45%88%Urinary Frequency30%61%Dysuria11%56%Urinary Urgency27%57%Bladder Spasm3%31%Hematuria11%29%Bladder Pain6%28%Urinary Incontinence7%22%Cystitis4%15%Nocturia2%7%Local Burning Symptoms –Procedure Related0%5%Urethral Pain0%3%Pelvic Pain1%1%Hematuria (Gross)0%1%TABLE 2 displays the adverse reactions other than local bladder symptoms that occurred in 1% or more of the 230 patients who received at least one dose of valrubicin intravesical solution in a clinical trial.                                                                                                                                      TABLE 2 Systemic Adverse Reactions (> 1%) Following Intravesical Administration of Valrubicin Intravesical Solution (N=230) Body System Preferred TermBody as a WholeAbdominal Pain5%Asthenia4%Headache4%Malaise4%Back Pain3%Chest Pain3%Fever2%CardiovascularVasodilation2%DigestiveNausea5%Diarrhea3%Vomiting2%Flatulence1%Hemic and LymphaticAnemia2%Metabolic and NutritionalHyperglycemia1%Peripheral Edema1%MusculoskeletalMyalgia1%NervousDizziness3%RespiratoryPneumonia1%Skin and AppendagesRash3%UrogenitalUrinary Tract Infection15%Urinary Retention4%Hematuria (miscroscopic)3%Adverse reactions other than local reactions that occurred in less than 1% of the patients who received valrubicin intravesical solution intravesically in clinical trials are listed below.     Digestive System: Tenesmus


    Metabolic and Nutritional: Nonprotein nitrogen increased


    Skin and Appendages: Pruritus


    Special Senses: Taste loss


    Urogenital System: Local skin irritation, poor urine flow, and urethritis

7  Drug Interactions

No drug interaction studies were conducted.

8.1  Pregnancy

Risk SummaryBased on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant females


[see Clinical Pharmacology (


12.1 and


12.3)]


.  There are no available data in pregnant females to inform the drug-associated risk.  In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions


[see Data].  Advise females who are or might become pregnant of the potential risk to a fetus.


In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.DataAnimal DataDaily intravenous administration of valrubicin to pregnant rats during the period of organogenesis at doses ≥ 12 mg/kg (about 0.2 times the recommended human intravesical dose on a mg/m


2 basis) was embryo-fetal toxic and teratogenic. Administration of 12 mg/kg resulted in fetal malformations. A dose of 24 mg/kg (about 0.3 times the recommended human intravesical dose on a mg/m


2 basis) caused numerous, severe alterations in the skull and skeleton of the developing fetuses. This dose also caused an increase in fetal resorptions and a decrease in viable fetuses.

8.2  Lactation

Risk SummaryThere are no data on the presence of valrubicin or its metabolites in human milk, the effects of valrubicin on the breast-fed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breast-fed infants from valrubicin, advise a lactating female not to breastfeed during treatment with valrubicin intravesical solution and for 2 weeks after the final dose.

8.3  Females And Males Of Reproduction Potential

ContraceptionFemalesValrubicin intravesical solution can cause fetal harm when administered to a pregnant female. Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months after the final dose


[see Use in Specific Populations (


8.1)]


.


MalesBased on genotoxicity findings, advise men with female partners of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 3 months following the final dose


[see Non Clinical Toxicology (


13.1)]


InfertilityMalesStudies of the effects of valrubicin intravesical solution on human male or female fertility have not been done. Based on findings in animal studies, Valrubicin intravesical solution may impair fertility in males of reproductive potential


[see Nonclinical Toxicology (


13.1)]


.

8.4  Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5  Geriatric Use

Because carcinoma


in situ of the bladder generally occurs in older individuals, 85% of the patients enrolled in the clinical studies of valrubicin intravesical solution were more than 60 years of age (49% of the patients were more than 70 years of age). In the primary efficacy studies, the mean age of the population was 69.5 years. There are no specific precautions regarding use of valrubicin intravesical solution in geriatric patients who are otherwise in good health.

10  Overdosage

There is no known antidote for overdoses of valrubicin intravesical solution. The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms.Myelosuppression is possible if valrubicin intravesical solution is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder rupture/perforation).  Under such inadvertent exposures in the peritoneal cavity, the expected toxicities include leukopenia and neutropenia, beginning within 1 week of dose administration, with nadirs by the second week, and recovery generally by the third week. If valrubicin intravesical solution is administered when bladder rupture or perforation is suspected, weekly monitoring of complete blood counts should be performed for 3 weeks.

11  Description

Valrubicin Intravesical Solution, USP contains valrubicin (N-trifluoroacetyladriamycin-14-valerate), which is a semisynthetic analog of the anthracycline doxorubicin as a cytotoxic agent. The chemical name of valrubicin is (2


S-


cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-


lyxo-hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethylpentanoate. Valrubicin is an orange or orange-red powder that is highly lipophilic, soluble in methylene chloride, ethanol, methanol and acetone, and relatively insoluble in water. Its chemical formula is C


34H


36F


3NO


13 and its molecular weight is 723.65. The chemical structure is shown in FIGURE 1.


FIGURE 1. Chemical Structure of ValrubicinValrubicin Intravesical Solution, USP is intended for intravesical administration in the urinary bladder. It is supplied as a nonaqueous solution that should be diluted before intravesical administration. Each vial of Valrubicin Intravesical Solution, USP contains 200 mg valrubicin at a concentration of 40 mg/mL in 5 mL of 50% polyoxyl castor oil/50% v/v dehydrated alcohol, USP without preservatives or other additives. The solution is sterile and nonpyrogenic.

12.1  Mechanism Of Action

Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G


2. Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II.

12.3  Pharmacokinetics

When 800 mg valrubicin intravesical solution was administered intravesically to patients with carcinoma


in situ, valrubicin intravesical solution penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytotoxicity to human bladder cells cultured


in vitro. During the two-hour dose-retention period, the metabolism of valrubicin intravesical solution to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol in bladder tissue was negligible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of valrubicin intravesical solution, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of valrubicin intravesical solution were absorbed into the plasma. N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol were measured in blood.


Total systemic exposure to anthracyclines during and after intravesical administration of valrubicin intravesical solution is dependent upon the condition of the bladder wall. The mean AUC


0-6hours (total anthracyclines exposure) for an intravesical dose of 900 mg of valrubicin intravesical solution administered 2 weeks after transurethral resection of bladder tumors (n=6) was 78 nmol/L•hr. In patients receiving 800 mg of valrubicin intravesical solution 5 to 51 minutes after typical (n=8) and extensive (n=5) TURB tumors, the mean AUC


0-6hours values for total anthracyclines were 409 and 788 nmol/L•hr, respectively. The AUC


0-6hours total exposure to anthracyclines was 18,382 nmol/L•hr in one patient who experienced a perforated bladder following a transurethral resection that occurred 5 minutes before administration of an intravesical dose of 800 mg of valrubicin intravesical solution. Administration of a comparable intravenous dose of valrubicin intravesical solution (600 mg/m


2; n=2) as a 24-hour infusion resulted in an AUC


0-6hours for total anthracyclines of 11,975 nmol/L•hr. These results are shown in FIGURE 2.


FIGURE 2. Comparison of Mean AUC0-6 hours in Valrubicin Intravesical Solution Clinical Studies (N=number of patients)

13.1  Carcinogenesis And Mutagenesis And Impairment Of Fertility

The carcinogenic potential of valrubicin has not been evaluated.In vitro, valrubicin was mutagenic in the bacterial reverse mutation (Ames) assayand clastogenic in the chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells.Studies in animals evaluating the effects of valrubicin on male or female fertility have not been conducted.  Based on effects on male reproductive organs in general toxicology studies in dogs with intravesical instillation, valrubicin may impair fertility in male patients.  When instilled into the bladder of male dogs weekly for 6 weeks, valrubicin caused mild to moderate atrophy of the prostate with inflammation, diffuse decrease in acinar size, epithelial changes.  It also caused testicular degeneration, marked germ cell depletion, spermatid giant cells and karyomegaly.

14  Clinical Studies

Valrubicin intravesical solution was administered intravesically to a total of 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses ranging from 200 to 900 mg. One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks. Patients receiving Valrubicin intravesical solution for refractory carcinoma in situ were monitored for disease recurrence or progression with cystoscopy, biopsy, and urine cytology every 3 months.In the 90 study patients with BCG-refractory carcinoma


in situ (CIS), 70% had received at least 2 courses of BCG and 30% had received one course of BCG and at least one additional course of treatment with another agent(s) - e.g., mitomycin, thiotepa, or interferon. Valrubicin intravesical solution was administered beginning at least two weeks after transurethral resection and/or fulguration.


After intravesical administration of valrubicin intravesical solution, 16 patients (18%) had a complete response documented by bladder biopsies and cytology at 6 months following initiation of therapy. Median duration of response from start of treatment varied according to the method of analysis (13.5 months if measured to last bladder biopsy without tumor and 21 months if measured until time of documented recurrence). A retrospective analysis in the 16 patients with complete response to valrubicin intravesical solution demonstrated that time to recurrence of their disease after treatment with valrubicin intravesical solution was longer than time to recurrence after previous courses of intravesical therapy.Of the 90 patients with BCG-refractory CIS, 11% (10 patients) developed metastatic or deeply-invasive bladder cancer during follow-up; four of these patients, none who underwent cystectomy, died with metastatic bladder cancer and six were found to have developed stage progression to deeply-invasive disease (T3), with lymph node involvement in one patient, at the time of cystectomy. It is uncertain to what extent the development of advanced bladder cancer in these patients was due to the delay in cystectomy required to receive treatment with valrubicin intravesical solution (3 months was the time of follow-up to determine response), as cystectomy was often delayed or was never performed despite failure of treatment with valrubicin intravesical solution. In the 10 patients documented to have invasive bladder cancer or metastatic disease, the delay between the time of treatment failure (when cystectomy should have been performed) and cystectomy or documentation of advanced bladder cancer was a median of 17.5 months.

15  References

  • OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html.

16  How Supplied

Valrubicin Intravesical Solution, USP is a sterile, clear red solution in polyoxyl castor oil/dehydrated alcohol, USP, containing 40 mg valrubicin per mL. Valrubicin Intravesical Solution, USP is available in single-use, clear glass vials, individually packaged in the following sizes:NDC 24201-101-04                                         Carton of four 200 mg/5 mL single-use vialsStore vials under refrigeration at 2°-8°C (36°-46°F) in the carton. DO NOT FREEZE.The container closure is not made with natural rubber latex.

17  Patient Counseling Information

  • Risk of Metastatic Bladder Cancer with Delayed CystectomyInform patients that valrubicin intravesical solution has been shown to induce complete responses in only about 1 in 5 patients, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal. Discuss the relative risk of cystectomy versus the risk of metastatic bladder cancer
  • [see Clinical Trials (
  • 14)]
  • And that the risk increases the longer cystectomy is delayed in the presence of persisting CIS.
  • Local Adverse Reactions Before and During TreatmentInform patients that the major acute toxicities from valrubicin intravesical solution are related to irritable bladder symptoms that may occur during instillation and retention of valrubicin intravesical solution and for a limited period following voiding
  • [see Adverse Reactions (
  • 6.1)]
  • .
  • Inform patients that for the first 24 hours following administration, red-tinged urine is typical.Advise patients to report prolonged irritable bladder symptoms or prolonged passage of red-colored urine immediately to their physician.Instruct patients to maintain adequate hydration following valrubicin intravesical solution treatment.Embryo-Fetal ToxicityAdvise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with valrubicin intravesical solution and for 6 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy
  • [see Warnings and Precautions (
  • 5.5), Use in Specific Populations (
  • 8.1 and
  • 8.3)]
  • .
  • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 3 months after the last dose
  • [see Use in Specific Populations (
  • 8.3)]
  • .
  • Lactation Advise females not to breastfeed during treatment with valrubicin intravesical solution and for 2 weeks after the last dose
  • [see Use in Specific Populations (
  • 8.2)]
  • .
  • Healthcare professionals can telephone Leucadia Pharmaceuticals (1-877-411-9681) for information on this product.Manufactured by:
  • The University of Iowa Pharmaceuticals
  • Iowa City, Iowa 52242
  • Manufactured for:
  • Leucadia Pharmaceuticals
  • Carlsbad, CA 92011
  • Rev. January 2019

* Please review the disclaimer below.

Previous Code
24201-010
Next Code
24201-237